Insider Trades66 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 13,143 | $0.73 | $19.7M | -65.44% | +30.95% | $9.6K | -2.23% | — | — |
| Jul 1, 2026 | Sell | LGVN | Devin Blass | CTO & SVP of CMC | 15,808 | $0.73 | $19.7M | -65.44% | +30.95% | $11.5K | -3.58% | — | — |
| Jul 1, 2026 | Sell | LGVN | Stephen H Willard | Chief Executive Officer | 18,046 | $0.73 | $19.7M | -65.44% | +30.95% | $13.2K | -2.29% | — | — |
| Jul 1, 2026 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 22,505 | $0.73 | $19.7M | -65.44% | +30.95% | $16.4K | -4.96% | — | — |
| Jul 1, 2026 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 22,505 | $0.73 | $19.7M | -65.44% | +30.95% | $16.4K | -4.83% | — | — |
| Apr 1, 2026 | Sell | LGVN | Stephen H Willard | Chief Executive Officer | 4,740 | $1.12 | $19.7M | -65.44% | +30.95% | $5.3K | -1.61% | — | — |
| Apr 1, 2026 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 5,611 | $1.12 | $19.7M | -65.44% | +30.95% | $6.3K | -1.63% | — | — |
| Apr 1, 2026 | Sell | LGVN | Devin Blass | CTO & SVP of CMC | 8,633 | $1.12 | $19.7M | -65.44% | +30.95% | $9.7K | -4.31% | — | — |
| Apr 1, 2026 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 13,145 | $1.12 | $19.7M | -65.44% | +30.95% | $14.7K | -5.74% | — | — |
| Apr 1, 2026 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 13,145 | $1.12 | $19.7M | -65.44% | +30.95% | $14.7K | -6.07% | — | — |
| Mar 2, 2026 | Sell | LGVN | Stephen H Willard | Chief Executive Officer | 105,533 | $0.55 | $19.7M | -65.44% | +30.95% | $57.5K | -26.38% | — | — |
| Jan 2, 2026 | Sell | LGVN | James Nathaniel Powell | Chief Executive Officer | 2,464 | $0.59 | $19.7M | -65.44% | +30.95% | $1.5K | -1.92% | — | — |
| Jan 2, 2026 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 6,952 | $0.59 | $19.7M | -65.44% | +30.95% | $4.1K | -1.98% | — | — |
| Jan 2, 2026 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 10,250 | $0.59 | $19.7M | -65.44% | +30.95% | $6.1K | -4.29% | — | — |
| Jan 2, 2026 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 10,250 | $0.59 | $19.7M | -65.44% | +30.95% | $6.1K | -4.52% | — | — |
| Jan 2, 2026 | Sell | LGVN | Devin Blass | CTO & SVP of CMC | 10,700 | $0.59 | $19.7M | -65.44% | +30.95% | $6.3K | -5.07% | — | — |
| Oct 1, 2025 | Sell | LGVN | James Nathaniel Powell | Chief Executive Officer | 2,389 | $0.74 | $19.7M | -65.44% | +30.95% | $1.8K | -1.83% | — | — |
| Oct 1, 2025 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 4,944 | $0.74 | $19.7M | -65.44% | +30.95% | $3.7K | -1.39% | — | — |
| Oct 1, 2025 | Sell | LGVN | Devin Blass | CTO & SVP of CMC | 7,609 | $0.74 | $19.7M | -65.44% | +30.95% | $5.6K | -3.48% | — | — |
| Oct 1, 2025 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 11,883 | $0.74 | $19.7M | -65.44% | +30.95% | $8.8K | -4.73% | — | — |
| Oct 1, 2025 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 11,883 | $0.74 | $19.7M | -65.44% | +30.95% | $8.8K | -4.98% | — | — |
| Jul 1, 2025 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 1,562 | $1.28 | $19.7M | -65.44% | +30.95% | $2.0K | -0.61% | — | — |
| Jul 1, 2025 | Sell | LGVN | Devin Blass | CTO & SVP of CMC | 4,599 | $1.28 | $19.7M | -65.44% | +30.95% | $5.9K | -3.80% | — | — |
| Jul 1, 2025 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 7,431 | $1.28 | $19.7M | -65.44% | +30.95% | $9.5K | -5.16% | — | — |
| Jul 1, 2025 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 7,431 | $1.28 | $19.7M | -65.44% | +30.95% | $9.5K | -5.14% | — | — |
| Jul 1, 2025 | Sell | LGVN | Mohamed Wa'El Ahmed Hashad | Chief Executive Officer | 13,146 | $1.28 | $19.7M | -65.44% | +30.95% | $16.8K | -5.17% | — | — |
| Jun 23, 2025 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 64,158 | $1.15 | $19.7M | -65.44% | +30.95% | $73.8K | -20.06% | — | — |
| May 16, 2025 | Sell | LGVN | Joshua Hare | Chief Scientific Officer | 5,250 | $1.40 | $19.7M | -65.44% | +30.95% | $7.4K | -0.72% | — | — |
| Apr 1, 2025 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 1,599 | $1.50 | $19.7M | -65.44% | +30.95% | $2.4K | -1.01% | — | — |
| Apr 1, 2025 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 7,566 | $1.50 | $19.7M | -65.44% | +30.95% | $11.3K | -4.97% | — | — |
| Apr 1, 2025 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 7,566 | $1.50 | $19.7M | -65.44% | +30.95% | $11.3K | -4.99% | — | — |
| Apr 1, 2025 | Sell | LGVN | Mohamed Wa'El Ahmed Hashad | Chief Executive Officer | 13,384 | $1.50 | $19.7M | -65.44% | +30.95% | $20.1K | -5.00% | — | — |
| Jan 2, 2025 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 1,205 | $1.79 | $19.7M | -65.44% | +30.95% | $2.2K | -0.76% | — | — |
| Jan 2, 2025 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 6,120 | $1.79 | $19.7M | -65.44% | +30.95% | $11.0K | -3.87% | — | — |
| Jan 2, 2025 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 6,120 | $1.79 | $19.7M | -65.44% | +30.95% | $11.0K | -3.88% | — | — |
| Jan 2, 2025 | Sell | LGVN | Mohamed Wa'El Ahmed Hashad | Chief Executive Officer | 10,827 | $1.79 | $19.7M | -65.44% | +30.95% | $19.4K | -3.89% | — | — |
| Oct 1, 2024 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 990 | $1.88 | $19.7M | -65.44% | +30.95% | $1.9K | -0.62% | — | — |
| Oct 1, 2024 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 5,316 | $1.88 | $19.7M | -65.44% | +30.95% | $10.0K | -3.26% | — | — |
| Oct 1, 2024 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 5,316 | $1.88 | $19.7M | -65.44% | +30.95% | $10.0K | -3.25% | — | — |
| Oct 1, 2024 | Sell | LGVN | Mohamed Wa'El Ahmed Hashad | Chief Executive Officer | 13,357 | $1.88 | $19.7M | -65.44% | +30.95% | $25.1K | -4.58% | — | — |
| Aug 15, 2024 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 14,035 | $2.46 | $19.7M | -65.44% | +30.95% | $34.5K | -7.24% | — | — |
| Aug 15, 2024 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 14,391 | $2.46 | $19.7M | -65.44% | +30.95% | $35.4K | -7.43% | — | — |
| Aug 15, 2024 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 31,505 | $2.46 | $19.7M | -65.44% | +30.95% | $77.5K | -9.36% | — | — |
| Aug 15, 2024 | Sell | LGVN | Mohamed Wa'El Ahmed Hashad | Chief Executive Officer | 39,248 | $2.46 | $19.7M | -65.44% | +30.95% | $96.6K | -24.78% | — | — |
| Jul 1, 2024 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 357 | $1.57 | $19.7M | -65.44% | +30.95% | $560.49 | -10.91% | — | — |
| Jun 3, 2024 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 325 | $1.04 | $19.7M | -65.44% | +30.95% | $338 | -0.23% | — | — |
| May 2, 2024 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 308 | $2.83 | $19.7M | -65.44% | +30.95% | $871.64 | -14.81% | — | — |
| May 2, 2024 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 410 | $2.83 | $19.7M | -65.44% | +30.95% | $1.2K | -11.13% | — | — |
| Apr 11, 2024 | Buy | LGVN | Mohamed Wa'El Ahmed Hashad | Chief Executive Officer | 10,638 | $2.35 | $19.7M | -65.44% | +30.95% | $25.0K | +54.23% | — | — |
| Apr 10, 2024 | Buy | LGVN | Joshua Hare | Chief Scientific Officer | 148,936 | $2.35 | $19.7M | -65.44% | +30.95% | $350.0K | +12.17% | — | — |
| Mar 12, 2024 | Sell | LGVN | Mohamed Wa'El Ahmed Hashad | Chief Executive Officer | 32,866 | $0.54 | $19.7M | -65.44% | +30.95% | $17.7K | -26.80% | — | — |
| Jan 2, 2024 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 992 | $1.32 | $19.7M | -65.44% | +30.95% | $1.3K | -0.69% | — | — |
| Jan 2, 2024 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 3,074 | $1.32 | $19.7M | -65.44% | +30.95% | $4.1K | -12.88% | — | — |
| Jan 2, 2024 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 4,098 | $1.32 | $19.7M | -65.44% | +30.95% | $5.4K | -10.01% | — | — |
| Jan 2, 2024 | Sell | LGVN | Mohamed Wa'El Ahmed Hashad | Chief Executive Officer | 5,123 | $1.32 | $19.7M | -65.44% | +30.95% | $6.8K | -10.77% | — | — |
| Oct 2, 2023 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 815 | $2.29 | $19.7M | -65.44% | +30.95% | $1.9K | -0.57% | — | — |
| Oct 2, 2023 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 3,059 | $2.29 | $19.7M | -65.44% | +30.95% | $7.0K | -11.36% | — | — |
| Oct 2, 2023 | Sell | LGVN | Lisa Locklear | Chief Financial Officer | 4,078 | $2.29 | $19.7M | -65.44% | +30.95% | $9.3K | -9.06% | — | — |
| Sep 21, 2023 | Buy | LGVN | Joshua Hare | Chief Scientific Officer | 5,000 | $3.00 | $19.7M | -65.44% | +30.95% | $15.0K | +0.01% | — | — |
| Sep 20, 2023 | Buy | LGVN | Paul T Lehr | General Counsel, Secretary | 2,000 | $3.00 | $19.7M | -65.44% | +30.95% | $6.0K | +0.23% | — | — |
| Sep 12, 2023 | Buy | LGVN | Mohamed Wa'El Ahmed Hashad | Chief Executive Officer | 10,000 | $3.00 | $19.7M | -65.44% | +30.95% | $30.0K | +1.28% | — | — |
| Sep 12, 2023 | Buy | LGVN | Joshua Hare | Chief Scientific Officer | 30,000 | $3.00 | $19.7M | -65.44% | +30.95% | $90.0K | +0.06% | — | — |
| Sep 1, 2023 | Sell | LGVN | Mohamed Wa'El Ahmed Hashad | Chief Executive Officer | 4,323 | $2.64 | $19.7M | -65.44% | +30.95% | $11.4K | -10.32% | — | — |
| Aug 18, 2023 | Sell | LGVN | Paul T Lehr | General Counsel, Secretary | 767 | $3.25 | $19.7M | -65.44% | +30.95% | $2.5K | -0.54% | — | — |
| Aug 18, 2023 | Sell | LGVN | Nataliya Agafonova | Chief Medical Officer | 3,081 | $3.36 | $19.7M | -65.44% | +30.95% | $10.4K | -10.27% | — | — |
| Aug 18, 2023 | Sell | LGVN | Mohamed Wa'El Ahmed Hashad | Chief Executive Officer | 4,292 | $3.25 | $19.7M | -65.44% | +30.95% | $13.9K | -9.29% | — | — |